• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Presbyopia-correcting IOL on display at AAO

Article

At the American Academy of Ophthalmology in Chicago, Johnson & Johnson Vision is spotlighting the Tecnis Symfony OptiBlue IOL, its presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology.

Johnson & Johnson Vision today announced availability of Tecnis Symfony OptiBlue IOL. its presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology.

This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins Tecnis Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver contrast and low-light performance across the PC-IOL category.1,2,3 The InteliLight portfolio will be on display at the American Academy of Ophthalmology's 2022 annual meeting in Chicago.

Cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes globally.1,2 Cataracts are a clouding of the lens in the eye, caused by a buildup of the eye’s natural protein which changes the way the eye focuses light, therefore changing the color and clarity of vision.3 Most people will develop cataracts at some point in their life, however cataracts can be treated with surgery; modern cataract surgery is a safe and effective treatment that has a success rate of nearly 98%.4

“My goal as an eye care professional is to deliver the best outcomes for my patients, and to help them get back to some of the activities many of us take for granted — driving at night, going up and down the stairs in their homes in dim light, or just going out at night and enjoying dinner at a restaurant, all with less risk”5 said Karolinne Rocha, MD, PhD, MUSC/Storm Eye Institute, Charleston, South Carolina “In my practice we’ve seen TECNIS Symfony OptiBlue IOL deliver good image contrast in the day and night, at all distances. Best of all, it has a minimized dysphotopsia profile that gives me the comfort I need to recommend presbyopia correction to more patients"

Tecnis Symfony OptiBlue IOL is powered by InteliLight, an innovative combination of three Johnson & Johnson Vision proprietary technologies: violet-light filter, echelette design and achromatic technology. The technology was first introduced in the Tecnis Synergy IOL.

  • Violet-Light Filter: Blocks the shortest wavelengths of light that produce the most light scatter,6,7,8 helping to mitigate halo, glare, and starbursts,9,10,11, and minimize visual disturbances when driving at night.11
  • Echelette Design: Helps reduce light scattering and halo intensity,9,12 making it easier to see digital devices.10,11

Achromatic Technology: Corrects chromatic aberration for better contrast day and night8,11 and superior performance across every distance.2,3

“We know our patients’ lives don’t stop at sunset, and neither should their confidence in being able to see clearly or drive at night,” said Nikki Sidi, vice president, Global Strategic Marketing, Surgical Vision, Johnson & Johnson Vision. “The InteliLight PCIOL portfolio delivers best-in-category* contrast and low-light performance.1,2,3 And with Tecnis Synergy for spectacle independence and TECNIS SymfonyOptiBlue for functional vision at every distance, surgeons can now choose the best in low-light performing PCIOLs, according to their patients’ needs.”

The Tecnis PC-IOL portfolio powered by InteliLight is now available for ophthalmologists to use in the U.S. and select countries in EMEA. The lenses in the portfolio, TECNIS Synergy IOL and TECNIS Symfony OptiBlue IOL, are also available in Toric II for excellent rotational stability1 for patients with astigmatism.

References

1 DOF2021CT4019 - Clinical investigation of rotational stability of the TECNIS™ Toric II IOL- Steele Study NXGT-202-QROS. 20 Aug. 2021.

2 World Health Organization - Priority Eye Diseases. REF 2016 OTH 0004.

3 World Health Organization. Blindness and Impairment. https://www.who.int/en/news-room/fact-sheets/detail/blindness-and-visual-impairment.

4 American Optometric Association. Cataract. https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/cataract?sso=y. Accessed May 24, 2022.

5 Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention. https://www.cdc.gov/visionhealth/basics/ced/index.html

6 Szanton SL, Walker RK, Roberts L, Thorpe RJ, Jr., Wolff J et al. 2015. Older adults' favorite activities are resoundingly active: findings from the NHATS study. Geriatr Nurs 36 (2): 131-135.

7 ARVO 2020_Effect of blocking violet light in extended depth of focus IOL: SC2019CT4056.

8 Mainster MA. Blue-blocking Intraocular Lenses: Myth or Reality? Am J Ophthalmol. 2009;1:8-10. REF2014CT0140 Blocks shortest wavelengths (p.1).

9 ARVO 2019_Optical and Visual performance of violet blocking IOL: SC2019CT4025

10 Effect of blocking violet light in EDOF IOLs. JNJ ArvoAbstractMay 2020/Optical and visual performance of violet blocking IOL SC2019CT4025.

11 DOF2020CT4011: DOF Effect of blocking violet light on light scatter in Tecnis Symfony™ IOLs (v1.0).

12 InteliLight US Sales Aid. PP2022MLT5751

Related Videos
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.